People | December 04, 2025
Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Here's a development that aims to keep your blood pressure in check. Literally!
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Subscribe To Our Newsletter & Stay Updated
